13F Pro Quality Score

21.7/100

Rank #2,655 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

89.3/100

Profitability

1.4/100

Balance Sheet

10.8/100

Earnings Quality

30.0/100

Free Cash Flow

1.2/100

Institutional Flow

1.7/100

Revenue Scale

0.6/100

Dilution Risk

1.7/100

RFL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Rafael Holdings, Inc. (RFL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RFL at 21.7/100 on a 32-signal composite quality model, placing it at rank #2,655 of 2,879 stocks — the bottom half of the AI-ranked universe. RFL scores in the top quartile across revenue growth (89.3). Areas of concern include revenue scale (0.6) and free cash flow (1.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), Rafael Holdings, Inc. reports quarterly revenue of $179.0K, net income of $-4.2M, free cash flow of $-7.3M. Top institutional holders of RFL by reported 13-F value include GEODE CAPITAL MANAGEMENT,, BlackRock,, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. RFL trades on the NYSE exchange and files with the SEC under CIK 1713863. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RFL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rafael Holdings, Inc. directly from SEC EDGAR. Rafael Holdings, Inc.'s 13F Pro composite quality score has ranged between 3 and 27 since 2021, currently 21.7 — an improving long-term trajectory across 20 quarterly and live scoring snapshots.

Fun facts about Rafael Holdings, Inc.

Quirks, history, and lore behind RFL — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. healthcare and real estate holding company · micro-cap · listed on NYSE American · headquartered in New Jersey.
  • 2
    The Numbers
    Revenue in the low tens of millions annually — this is not a giant pharma, it's a small holding company with a focused portfolio of assets and investments.
  • 3
    The History
    Spun off from a larger company around 2018, it inherited a mix of pharmaceutical royalty interests and commercial real estate holdings — an unusual pairing, to say the least.
  • 4
    The Secret
    Its healthcare arm holds interests tied to cancer treatment drugs, while its real estate side owns properties in Israel and New Jersey — yes, really.
  • 5
    The Lore
    It has ties to IDT Biologika and oncology-focused assets, and its Israeli real estate connections reflect the background of the family that controls it — the Jonas family.
  • 6
    The Giveaway
    Named after the Archangel Rafael, this Jonas family-controlled holding company trades under a three-letter ticker and straddles cancer drug royalties and Israeli real estate.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$179.0K

Net Income

Q3 2026

$-4.2M

Free Cash Flow

Q3 2026

$-7.3M

Get alerted when RFL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rafael Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of RFL

Put RFL on your watchlist

Track score changes the day Rafael Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is RFL a good stock to buy?

13F Pro's AI-powered analysis of Rafael Holdings, Inc. (RFL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RFL are available on the RFL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RFL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RFL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rafael Holdings, Inc.'s investment landscape.